ZELSUVMI (Berdazimer Sodium) Patent Expiration, LOE Window & CMS Spending

ZELSUVMI (Berdazimer Sodium) by Lnhc: FDA Orange Book core substance LOE 2035-07-10, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,950 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLnhc
FDA Application & PathwayN217424 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-07-10
Last Listed Patent or Exclusivity Date2035-07-10
Orange Book Patents (*PED Extensions)22 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,950 intro WAC)